Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.

Abstract

PURPOSE:

The aim of this study was to evaluate the efficacy of post-operative radioiodine ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in patients with differentiated thyroid carcinoma (DTC). We also aimed to assess the prognostic role of several patient features on the outcome of ablation.

METHODS:

We retrospectively analyzed data from a total of 125 patients with DTC who underwent post-operative radioiodine ablation with 1,850 MBq of ¹³¹I after preparation with rhTSH. One injection of 0.9 mg rhTSH was administered on each of two consecutive days; ¹³¹I therapy was delivered 24 h after the last injection, followed by a post-therapy whole-body scan. Successful ablation was assessed 6-12 months later and defined as an rhTSH-stimulated serum thyroglobulin (Tg) level ≤1.0 ng/ml and a normal neck ultrasound.

RESULTS:

Patients were stratified according to the American Thyroid Association (ATA) Management Guidelines for Differentiated Thyroid Cancer. Successful ablation was achieved in 82.4 % of patients, with an ablation rate of 95.1 % in low-risk patients and 76.2 % in intermediate-risk patients. Analyzing the correlation between ablation outcome and patient characteristics, we found a statistically significant association between failure to ablate and class of risk based on ATA guidelines (p = 0.025) and a stimulated Tg value at ablation of above 5 ng/ml (p < 0.001).

CONCLUSION:

The use of 1,850 MBq post-operative radioiodine thyroid remnant ablation in association with rhTSH is effective for low- and intermediate-risk patients. Moreover, in our study, we found a statistical correlation between failure to ablate and class of risk based on ATA guidelines for DTC and a stimulated Tg value at ablation.

• Authors: Alberto S Tresoldi, Laura F Sburlati, Marcello Rodari, Mink S Schinkelshoek, Michela Perrino, Simone De Leo, Laura Montefusco, Paolo Colombo, Maura Arosio, Andrea Gerardo Antonio Lania, Laura Fugazzola, Arturo Chiti
• Journal: Journal of endocrinological investigation (J Endocrinol Invest) Vol. 37 Issue 8 Pg. 709-714 (08 2014) ISSN: 1720-8386 [Electronic] Italy
• PMID: 24844565 (Publication Type: Journal Article)

Chemical References

• Iodine Radioisotopes
• Radiopharmaceuticals
• Recombinant Proteins
• Thyrotropin

Topics

• Adenocarcinoma, Follicular (drug therapy, pathology, radiotherapy, surgery)
• Adult
• Carcinoma (drug therapy, pathology, radiotherapy, surgery)
• Carcinoma, Papillary (drug therapy, pathology, radiotherapy, surgery)
• Carcinoma, Papillary, Follicular (drug therapy, pathology, radiotherapy, surgery)
• Chemoradiotherapy, Adjuvant
• Combined Modality Therapy
• Female
• Humans
• Iodine Radioisotopes (therapeutic use)
• Italy (epidemiology)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (epidemiology, prevention & control)
• Neoplasm Staging
• Neoplasm, Residual (epidemiology, prevention & control)
• Radiopharmaceuticals (therapeutic use)
• Recombinant Proteins (therapeutic use)
• Retrospective Studies
• Risk
• Thyroid Cancer, Papillary
• Thyroid Gland (drug effects, pathology, radiation effects, surgery)
• Thyroid Neoplasms (drug therapy, pathology, radiotherapy, surgery)
• Thyroidectomy
• Thyrotropin (genetics, therapeutic use)
• Whole Body Imaging